de Botton, S., Fenaux, P., Yee, K., Récher, C., Wei, A. H., Montesinos, P., Taussig, D. C., Pigneux, A., Braun, T., Curti, A., Grove, C., Jonas, B. A., Khwaja, A., Legrand, O., Peterlin, P., Arnan, M., Blum, W., Cilloni, D., Hiwase, D. K., … Cortes, J. (2023). Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Advances, 7(13), 3117–3127. https://doi.org/10.1182/bloodadvances.2022009411
Subjects:
Quinolines
(MeSH)
Leukemia, Myeloid, Acute
(MeSH)
Publication Type:
Article
Unique ID:
10.1182/bloodadvances.2022009411
PMID:
Journal:
Publication Date:
Data Source:
PubMed
Source Link: